

Summary of the ANNEX EU4Health –work programme for 2024

This is the summary of the Annex to the Commission Implementing Decision of the EU4Health programme for 2024¹, which sets out priorities and actions, including the allocation of resources, for the implementation in 2024 of the EU4Health programme as established under Regulation (EU) 2021/522 of the European Parliament and of the Council² (‘the EU4Health Regulation’).

The overall budget for 2024 amounts to **EUR 752 449 856³** of which EUR 355 950 000 will be grants, EUR 318 443 856 will be procurement and EUR 3 400 000 will be other expenditures (all under direct management) and EUR 74 656 000 will be under indirect management.

The EU4Health programme represents an unprecedented level of financial commitment for the EU in the area of health in comparison with the previous health programmes.

The general objectives and specific objectives of the EU4Health programme are laid down in Articles 3 and 4 of Regulation (EU) 2021/522 and are implemented based on the **strands** and **areas of actions** set out in the table below.

Table: Strands & areas of action

STRANDS & AREAS OF ACTION	2024 budget (in EUR)
1. CRISIS PREPAREDNESS (CP)	485 517 000
HEALTH EMERGENCY PREPAREDNESS AND RESPONSE AUTHORITY (HERA)	470 817 000
TACKLING ANTIMICROBIAL RESISTANCE ⁴	1 600 000
IMPLEMENTATION OF THE REGULATION ON SERIOUS CROSS-BORDER THREATS TO HEALTH	12 600 000
STERILE INSECT TECHNIQUE AS A TOOL TO ELIMINATE THE YELLOW FEVER MOSQUITO (AEDES AEGYPTI) IN CYPRUS	500 000
2. HEALTH PROMOTION AND DISEASE PREVENTION (DP)	70 900 000
TOBACCO CONTROL POLICY	2 500 000
NON-COMMUNICABLE AND COMMUNICABLE DISEASES ⁵	45 000 000
MENTAL HEALTH CHALLENGES ⁶	10 000 000

¹ https://ec.europa.eu/health/funding/programme_en (English only).

² Regulation (EU) 2021/522 of the European Parliament and of the Council of 24 March 2021 establishing a Programme for the Union’s action in the field of health (‘EU4Health Programme’) for the period 2021-2027 and repealing Regulation (EU) No 282/2014 (OJ L 107, 26.3.2021, p. 1).

³ The amount includes EFTA contributions.

⁴ Including CA WHO, CA OECD.

⁵ Including CA OECD and cancer-related actions.

EUROPEAN ENVIRONMENT AGENCY	400 000
OPERATING GRANTS FOR HEALTH NGOs	9 000 000
EU4HEALTH NATIONAL FOCAL POINTS	2 000 000
SUPPORTING LONG-COVID PATIENTS: INSIGHTS AND ACTION	2 000 000
3. CANCER (CR)	117 600 000
STRENGTHENING DIGITAL CAPABILITIES	20 000 000
PERSONALISED CANCER MEDICINE ⁷	30 900 000
PAEDIATRIC PALLIATIVE CARE	14 500 000
INTEGRATION OF CANCER IMAGES INTO THE FEDERATED PAN-EUROPEAN INFRASTRUCTURE TO FOSTER SCREENING PROGRAMMES	8 000 000
EUROPEAN GUIDELINES AND QUALITY ASSURANCE SCHEME FOR GASTRIC CANCER SCREENING AND CARE	6 500 000
HEALTH LITERACY FOR CANCER PREVENTION AND CARE.	5 000 000
CANCER REGISTRY DATA FEEDING INTO THE EUROPEAN CANCER INFORMATION SYSTEM	13 000 000
RADIATION SAFETY AND QUALITY OF COMPUTED TOMOGRAPHY IMAGING OF CHILDREN AND YOUNG ADULTS	3 000 000
PSYCHOSOCIAL SUPPORT AND REHABILITATION FOR CHILDREN AND THEIR FAMILIES IN PAEDIATRIC ONCOLOGY CLINICS IN MEMBER STATES AND COUNTRIES ASSOCIATED TO THE EU4HEALTH PROGRAMME	7 400 000
EU NETWORK OF YOUTH CANCER SURVIVORS	5 000 000
PROVISION OF CARE FOR ADOLESCENT AND YOUNG ADULT CANCER PATIENTS	1 000 000
SUPPORT FOR THE SUBGROUP ON CANCER UNDER THE EXPERT GROUP ON PUBLIC HEALTH	500 000
BOOSTING CANCER PREVENTION THROUGH MAINTENANCE OF THE EU CANCER APP	1 800 000
SUPPORT SETTING UP NEW NETWORKS OF EXPERTISE ON CANCER AND CANCER CONDITIONS	1 000 000
4. HEALTH SYSTEMS AND HEALTHCARE WORKFORCE (HS)	41 404 000
REFORMING AND STRENGTHENING HEALTH SYSTEMS ⁸	2 000 000
PREPARATION AND IMPLEMENTATION OF THE HEALTH TECHNOLOGY ASSESSMENT REGULATION	650 000

⁶ Including CA UNICEF.

⁷ Including direct grants to Member States and a call for proposals covering metastatic cancer.

⁸ Including CA WHO Europe and membership fee the WHO EU Observatory.

IMPLEMENTATION OF THE PHARMACEUTICAL LEGISLATION AND STRATEGY ⁹	8 516 000
STRENGTHENING THE IMPLEMENTATION OF THE LEGISLATION ON BLOOD, TISSUES AND CELLS AND ORGANS ¹⁰	15 278 000
CROSS-BORDER HEALTHCARE	200 000
IMPLEMENTATION OF REGULATIONS ON MEDICAL DEVICES AND IN VITRO DIAGNOSTIC MEDICAL DEVICES	13 950 000
HEALTH POLICY TRAINING	810 000
5. DIGITAL (DI)	25 750 000
COMMUNICATION AND INFORMATION ACTIVITIES FOR THE PROPOSED EUROPEAN HEALTH DATA SPACE	1 600 000
PRIMARY USES OF HEALTH DATA IN THE PROPOSED EUROPEAN HEALTH DATA SPACE	11 500 000
SECONDARY USES OF HEALTH DATA IN THE PROPOSED EUROPEAN HEALTH DATA SPACE	2 650 000
COMPLIANCE CHECKS FOR EUROPEAN HEALTH DATA SPACE INFRASTRUCTURES	1 500 000
PROMOTING AND DEVELOPING DIGITAL SOLUTIONS AT INTERNATIONAL LEVEL	4 000 000
PROMOTING THE UPTAKE OF ARTIFICIAL INTELLIGENCE IN HEALTH	4 500 000
6. OTHER ACTIONS	11 278 856
CONFERENCE – PRESIDENCY OF THE COUNCIL OF EUROPEAN UNION	200 000
ORGANISATION OF CONFERENCE AND EVENTS	450 000
SCIENTIFIC COMMITTEES	710 000
HEALTH POLICY PLATFORM	500 000
COMMUNICATION ACTIVITIES	3 370 500
STUDIES	708 356
TRANSLATION SERVICES	120 000
RECURRENT IT ACTIVITIES	4 150 000
JOINT AUDIT ASSESSMENT ¹¹	170 000
EUROPEAN HEALTH AND DIGITAL EXECUTIVE AGENCY (HaDEA) EXPERT EVALUATORS	400 000
HERA IMPACT ASSESSMENTS	500 000

The **actions proposed for funding** are set out in the bullet points below and cover six main areas: (i) action grants; (ii) operating grants (iii) procurement; (iv) IT support; (v) other actions under direct management; and (vi) actions under indirect management.

⁹ Including ICH and IPRP.

¹⁰ Including CA Council of Europe/EDQM.

¹¹ Including the International Medical Device Regulatory Forum.

Action grants

Calls for proposals to support:

- a) the European Hub for vaccine development – HERA;
- b) developing and fostering innovation in next-generation respiratory protection – HERA;
- c) innovative manufacturing technologies and processes in the Union for medicines production – HERA;
- d) the development of novel antivirals – HERA;
- e) a comprehensive and prevention-oriented approach to mental health in the EU;
- f) health promotion and prevention of non-communicable and communicable diseases, including vaccine-preventable cancers and other cancers caused by infections, and disease prevention including smoke- and aerosol-free environments;
- g) integrating cancer images into the federated pan-European infrastructure to foster screening programmes;
- h) increasing health literacy for cancer prevention and care;
- i) radiation safety and the quality of computed tomography imaging of children and young adults;
- j) the development of social services for psychosocial support and rehabilitation for children and their families in paediatric oncology clinics in Member States and countries associated to the EU4Health programme;
- k) the EU Network of Youth Cancer Survivors;
- l) personalised cancer medicine;
- m) setting up new networks of expertise on cancer and cancer conditions;
- n) advancing the adoption of artificial intelligence in health.

Grants for actions co-financed with Member States' authorities / joint actions:

- a) supporting the development of sustainable, forward-looking national and Union stockpiling strategies – HERA;
- b) fighting cancers caused by infections and vaccine-preventable cancers and addressing communicable diseases (HIV/AIDS, TB, hepatitis);
- c) strengthening digital capabilities, including e-health, telemedicine, remote monitoring systems, access to health data and health data exchange services in cancer centres in the EU;
- d) personalised cancer medicine;
- e) paediatric palliative care;
- f) supporting the improvement of the quality of cancer registry data feeding into the European Cancer Information System;
- g) health promotion and disease prevention, including smoke- and aerosol-free environments;
- h) promoting a comprehensive, prevention-oriented approach to mental health to support vulnerable groups;
- i) promoting effective use of regulatory flexibilities including the use of magistral preparations that might be used to mitigate certain shortages;
- j) stepping up national efforts and collaboration among competent national authorities;
- k) expansion of the MyHealth@EU digital service infrastructure with a wider range of services and to more Member States;
- l) supporting national focal points in providing guidance, information and assistance related to the promotion and implementation of EU health legislation and the EU4Health programme.

Other direct grants to support:

- a) the operation of the EU Reference Laboratories in accordance with Regulation (EU) 2022/2371 on serious cross-border threats to health;
- b) EU Reference Laboratories for the EU contribution on in vitro diagnostic medical devices (under Regulation (EU) 2017/746).

Operating grants:

Calls for proposals to support:

- a) health NGOs with operating grants in 2024;
- b) health NGOs with framework partnership agreement for operating grants (2025-2026).

Procurement under direct management:

- a) ever-warm facilities (EU FAB) for vaccines production – HERA;
- b) speed up the development of access to and/or uptake of medical countermeasures including critical medicines (other than vaccines) – HERA;
- c) innovation, supply capacities and access to critical medicines and antimicrobials – HERA;
- d) gathering intelligence on priority threats and medical countermeasures – HERA;
- e) setting up a global wastewater sentinel system – HERA;
- f) purchase innovation and deployment of medical countermeasures in emergency situations – HERA;
- g) training and exercise programme for management of medical countermeasures – HERA;
- h) study supporting the evaluation of the European Centre for Disease Prevention and Control;
- i) organisation of training on preparedness and response to serious cross-border health threats;
- j) tobacco control policy: implementation and modernisation of tobacco control legislation;
- k) Tobacco Products Directive (2014/40/EU) – characterising flavours: operation of a technical group;
- l) technical implementation of the Tobacco Products Directive (2014/40/EU);
- m) development of European guidelines and a quality assurance scheme for gastric cancer prevention and care; preparing the third report on the status of implementation of the Council Recommendations on cancer screening;
- n) exploratory study on the provision of care for adolescent and young adult cancer patients in the EU;
- o) boosting cancer prevention through continued maintenance of the EU cancer prevention app;
- p) cross-border healthcare (Directive 2011/24/EU): review how much existing EU legislation applies to telemedicine services;
- q) implementation of pharmaceutical legislation and a data-driven policy for medical products;
- r) support pharmaceutical inspections in Member States;
- s) study on the implementation of Regulation (EU) 536/2014 on clinical trials of medicinal products for human use;
- t) coherence of legislation on therapies based on substances of human origin (SoHO);
- u) organisational support to Member States to implement the new Regulation on SoHO;
- v) implementation of the legal framework for cross-border healthcare: review the applicability of existing EU legislation to telemedicine services;
- w) horizon scanning for medical devices;

- x) studies supporting the evaluation of Regulation (EU) 2017/745 and Regulation (EU) 2017/746;
- y) translating medical devices and in vitro diagnostics nomenclature;
- z) support for guidance documents in the field of medical devices and in vitro diagnostics;
- aa) programme of continuous learning in a European Health Union professional network;
- bb) communication and information activities to support the roll out and use of the European Health Data Space and its services;
- cc) support centre for the European Electronic Health Record Exchange Format and for the interoperability and security of electronic health record systems;
- dd) support to key stakeholders and HealthData@EU participants in the scope of the European Health Data Space;
- ee) operations and further development of HealthData@EU (central services);
- ff) compliance checks for the infrastructure of the European Health Data Space.

IT support:

- a) data analytics;
- b) support to the European Medicinal Products Database;
- c) Tobacco Products Directive: operation of IT databases;
- d) support to EUDAMED (European database on medical devices);
- e) development of SoHO digital platform – SoHO-X.

Other:

Annual membership fees for international organisations and regulatory bodies and other contributions.

- a) International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use;
- b) International Pharmaceutical Regulators Programme;
- c) administrative support to the National Competent Authorities on Pricing and Reimbursement;
- d) European Observatory of Health Systems and Policies;
- e) reducing the burden of disease on public health;
- f) scientific, technical and administrative support for EU Reference Laboratories and Expert Laboratories in the field of in vitro diagnostics and medical devices respectively;
- g) meetings of standing committees, ad hoc meetings, committees and other events;
- h) HaDEA expert evaluators;
- i) European Climate and Health Observatory;
- j) Member States' participation in the mutual-recognition agreements on monitoring/audits in the pharmaceuticals field;
- k) services for administrative, logistic and communication support to the secretariat of the Member State Coordination Group on Health Technology Assessment (HTA) and the HTA Stakeholder Network;
- l) Conference – launch of the application of Regulation (EU) 2021/2282 on health technology assessment;
- m) support to the technical secretariat of the Notified Bodies Coordination Group;
- n) joint assessment of notified bodies;
- o) support to the peer review and exchange of experience between authorities responsible for notified bodies;
- p) technical and administrative support to the Medical Device Coordination Group;

- q) administrative, logistic and scientific support for the Subgroup on Cancer under the Commission's expert group on public health and for the EU-US Health Task Force on Cancer;
- r) events organised by the Presidency of the Council of the European Union;
- s) contribution to the organisation of conferences and events.

Actions implemented under indirect management:

- a) European Investment Bank – blending under the thematic innovation financial product implemented by the European Investment Bank under the InvestEU Fund – HERA;
- b) Global Fund – to support the implementation of the diagnostics component of the 100 days mission – HERA;
- c) WHO and UNEP – to support strategies, capacity and data for global wastewater and environmental surveillance – HERA;
- d) WHO – to support the development of antibiotics to strengthen global preparedness and response – HERA;
- e) WHO – to support logistical operations for medical countermeasures in Africa – HERA;
- f) WHO – to strengthen global health by promoting and developing digital solutions at international level;
- g) ECDC – strengthening the EU Early Warning and Response System to align it with the Serious cross-border threats Regulation for 2024-2027;
- h) OECD – antimicrobial resistance action and projections;
- i) EFSA, ECHA, EEA, EMCDDA, Europol, EMA – public health risk assessments;
- j) International Atomic Energy Agency (IAEA) – sterile insect technique as a tool to eliminate the yellow fever mosquito (*Aedes aegypti*) in Cyprus; build capacity to use this vector control technique in the EU;
- k) WHO – antimicrobial resistance and healthcare-associated infections;
- l) WHO and OECD - supporting long-COVID patients: insights and action;
- m) UNICEF – promoting a comprehensive and prevention-oriented approach to children's health;
- n) OECD – health promotion and disease prevention: reducing the burden of NCDs, including cancers caused by infections and vaccine-preventable cancers, and promoting mental health;
- o) WHO – nurses at the heart of more resilient health systems and safe healthcare;
- p) Council of Europe – European Directorate for the Quality of Medicines & HealthCare – to support SoHO;
- q) European Medicines Agency – electronic product information.